BackgroundAcute myocardial infarction (AMI) was considered to be one of the major causes of morbidity and mortality worldwide. In order to manage the acute myocardial infarction outbreaks, accurate biomarkers for risk prediction are needed. Circulating microRNAs (miRNAs) may act as diagnostic and prognostic biomarkers for cardiovascular events.MethodsThis study aimed to determine the possibility of circulating miRNAs used as biomarkers for AMI and their dynamic expression levels before and after percutaneous coronary intervention (PCI) in patients. Circulating miR-26a-1, miR-27a, miR-30d, miR-146a, miR-199a-1 and miR-423 were selected and validated in 31 AMI patients and 27 matched controls by quantitative real-time PCR (qPCR).ResultsThe expression levels of plasma miR-26a-1, miR-146a and miR-199a-1 were significantly increased in AMI patients. Receiver operating characteristic (ROC) analysis indicated that miR-26a-1, miR-146a and miR-199a-1 showed considerable diagnostic efficiency for predicting AMI. Furthermore, we demonstrated that the combination of miR-26a-1, miR-146a and miR-199a-1 facilitated AMI diagnosis.ConclusionsOur findings suggest that circulating miR-26a-1, miR-146a and miR-199a-1 have the potential to be used as biomarkers for AMI diagnosis.

中文翻译：

---

循环 miR-26a-1、miR-146a 和 miR-199a-1 是急性心肌梗死的潜在候选生物标志物

背景急性心肌梗死（AMI）被认为是全世界发病和死亡的主要原因之一。为了管理急性心肌梗死的爆发，需要准确的生物标志物来进行风险预测。循环microRNA (miRNA)可能作为心血管事件的诊断和预后生物标志物。方法本研究旨在确定循环miRNA作为AMI生物标志物的可能性及其在患者经皮冠状动脉介入治疗(PCI)前后的动态表达水平。通过定量实时 PCR (qPCR) 在 31 名 AMI 患者和 27 名匹配对照中选择并验证了循环 miR-26a-1、miR-27a、miR-30d、miR-146a、miR-199a-1 和 miR-423。结果AMI患者血浆miR-26a-1、miR-146a、miR-199a-1表达水平显着升高。受试者工作特征 (ROC) 分析表明 miR-26a-1、miR-146a 和 miR-199a-1 在预测 AMI 方面表现出相当大的诊断效率。此外，我们证明 miR-26a-1、miR-146a 和 miR-199a-1 的组合有助于 AMI 诊断。结论我们的研究结果表明，循环 miR-26a-1、miR-146a 和 miR-199a-1 具有潜力用作 AMI 诊断的生物标志物。